EBS
Emergent Biosolutions Inc (EBS)
Healthcare • NYSE • $9.50+4.05%
- Symbol
- EBS
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $9.50
- Daily Change
- +4.05%
- Market Cap
- $490.16M
- Trailing P/E
- N/A
- Forward P/E
- 3.18
- 52W High
- $14.06
- 52W Low
- $5.31
- Analyst Target
- $12.00
- Dividend Yield
- N/A
- Beta
- 2.33
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the tre…
Company websiteResearch EBS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.